Press Releases

CORAL GABLES, Fla. , Nov. 26, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological

- Firdapse ® Launch Momentum Continues with Q3 Net Revenues of $30.9 Million -Third Quarter GAAP Net Income of $13.6 Million -Catalyst Provides Net Revenue Guidance – Approximately $100 Million for FY 2019 and range of $135 Million to $155 Million for FY 2020 -Company to Host Quarterly Conference

CORAL GABLES, Fla. , Oct. 31, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today

CMS-001 trial is the first and only double-blinded, placebo-controlled study ever conducted in genetically confirmed CMS patients Results in full population across all tested subtypes of CMS did not achieve statistical significance for the primary or secondary endpoints MuSK-Myasthenia Gravis Phase

CORAL GABLES, Fla. , Sept. 25, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today

CORAL GABLES, Fla. , Sept. 23, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc.  (NasdaqCM: CPRX) is commenting on today's trading activity in its common stock and on the current state of its capital resources. The Company is reporting that it is not aware of any information about the

CORAL GABLES, Fla. , Sept. 13, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc.  (NasdaqCM: CPRX) today announced that it will not conclude the offering of shares of its common stock announced on Wednesday, September 11, 2019 . The Company believes that the culmination of an offering at the

CORAL GABLES, Fla. , Sept. 11, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (NasdaqCM: CPRX) announced today that it has commenced an underwritten public offering of 8.0 million shares of its common stock. Catalyst also intends to grant the underwriters a 30-day option to purchase up to

CORAL GABLES, Fla. , Aug. 28, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today

Firdapse ® Launch Momentum Continues with Second Quarter Net Revenues of $28.8 Million 409 Adult LEMS Patients Active on Firdapse as of June 30, 2019 Company to Host Quarterly Conference Call at 8:30 am ET Tomorrow CORAL GABLES, Fla. , Aug. 07, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals,